Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.850
-0.510 (-9.51%)
At close: Jun 18, 2026, 4:00 PM EDT
4.899
+0.049 (1.02%)
After-hours: Jun 18, 2026, 7:59 PM EDT
Achieve Life Sciences Employees
Achieve Life Sciences had 28 employees as of December 31, 2025. The number of employees increased by 3 or 12.00% compared to the previous year.
Employees
28
Change (1Y)
3
Growth (1Y)
12.00%
Revenue / Employee
n/a
Profits / Employee
-$1,856,750
Market Cap
497.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 3 | 12.00% |
| Dec 31, 2024 | 25 | 3 | 13.64% |
| Dec 31, 2023 | 22 | 2 | 10.00% |
| Dec 31, 2022 | 20 | 4 | 25.00% |
| Dec 31, 2021 | 16 | 3 | 23.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| Ginkgo Bioworks Holdings | 485 |
| Prime Medicine | 146 |
| Aclaris Therapeutics | 73 |
| Tectonic Therapeutic | 60 |
| Candel Therapeutics | 55 |
| Crescent Biopharma | 55 |
ACHV News
- 10 days ago - Achieve Life Sciences Proxy statement: Proxy filing - Filings
- 16 days ago - Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - GlobeNewsWire
- 20 days ago - Achieve Life Sciences Proxy statement: Proxy filing - Filings
- 4 weeks ago - Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - GlobeNewsWire
- 5 weeks ago - Achieve Life Sciences files prospectus for resale of shares by holders - TheFly
- 5 weeks ago - Achieve Life Sciences Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - Achieve Life Sciences Earnings release: Q1 2026 - Filings
- 5 weeks ago - Achieve Life Sciences Quarterly report: Q1 2026 - Filings